[go: up one dir, main page]

MX2011011960A - Peptidos penetradores de celulas. - Google Patents

Peptidos penetradores de celulas.

Info

Publication number
MX2011011960A
MX2011011960A MX2011011960A MX2011011960A MX2011011960A MX 2011011960 A MX2011011960 A MX 2011011960A MX 2011011960 A MX2011011960 A MX 2011011960A MX 2011011960 A MX2011011960 A MX 2011011960A MX 2011011960 A MX2011011960 A MX 2011011960A
Authority
MX
Mexico
Prior art keywords
cell membrane
acid sequence
amino acid
peptide
permeability
Prior art date
Application number
MX2011011960A
Other languages
English (en)
Inventor
Reiji Nishio
Mariko Morishita
Kozo Takayama
Nobuo Ida
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of MX2011011960A publication Critical patent/MX2011011960A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Insects & Arthropods (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un péptido penetrador de célula descrito en cualquiera de (A) a (D) que da permeabilidad a membrana celular y además capacidad de absorción transmucosa a una sustancia fisiológicamente activa: (A) un péptido que tiene la secuencia de aminoácidos representada por SEQ ID NO:1; (B) un péptido que tiene una secuencia de aminoácidos que es la misma que la secuencia de aminoácidos representada por SEQ ID NO:1 excepto que uno o varios aminoácidos básicos se sustituyen, se suprimen, se insertan y/o se adicionan, péptido que tiene permeabilidad en membrana celular; (C) un péptido que tiene una secuencia de aminoácidos que es la misma que la secuencia de aminoácidos representada por SEQ ID NO:1, excepto que de 1 a 5 aminoácidos se sustituyen, se suprimen, se insertan y/o se adicionan, cuyo péptido tiene, permeabilidad en membrana celular; (D) un péptido que tiene: una secuencia de aminoácidos representada por la secuencia inversa de cualquiera de (A) a (C); una secuencia de aminoácidos que es la misma que la secuencia de aminoácidos representada por la secuencia inversa de (A), excepto que uno o varios aminoácidos básicos se sustituyen, se suprimen, se insertan y/o se adicionan; o una secuencia de aminoácidos que es la misma que la secuencia de aminoácidos representada por la secuencia inversa de (A) excepto que de 1 a 5 aminoácidos se sustituyen, se suprimen, se insertar y/o adicionan; cuyo péptido tiene permeabilidad en membrana celular.
MX2011011960A 2009-05-20 2010-05-19 Peptidos penetradores de celulas. MX2011011960A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009122096 2009-05-20
JP2010071774 2010-03-26
PCT/JP2010/058420 WO2010134537A1 (ja) 2009-05-20 2010-05-19 細胞膜透過性ペプチド

Publications (1)

Publication Number Publication Date
MX2011011960A true MX2011011960A (es) 2011-12-06

Family

ID=43126214

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011960A MX2011011960A (es) 2009-05-20 2010-05-19 Peptidos penetradores de celulas.

Country Status (13)

Country Link
US (1) US8772449B2 (es)
EP (1) EP2433953B1 (es)
JP (1) JP5653214B2 (es)
KR (1) KR101783291B1 (es)
CN (1) CN102428096B (es)
AU (1) AU2010250452B2 (es)
BR (1) BRPI1008230B1 (es)
CA (1) CA2762551C (es)
ES (1) ES2546304T3 (es)
MX (1) MX2011011960A (es)
PL (1) PL2433953T3 (es)
RU (1) RU2548807C2 (es)
WO (1) WO2010134537A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102580061B (zh) * 2011-12-01 2015-04-22 武汉健宇生物医药科技有限公司 一种鼻用型胰岛素制剂及制备方法
CN115927242A (zh) 2012-05-11 2023-04-07 珍白斯凯尔有限公司 具有抗炎活性的肽及其在制备抗炎组合物中的应用
CN104507489B (zh) 2012-05-11 2016-07-13 杰姆维克斯&凯尔有限公司 用于预防和治疗类风湿性关节炎的组合物
ES2981865T3 (es) 2012-07-11 2024-10-10 Gemvax & Kael Co Ltd Conjugado que comprende un péptido de penetración celular y composiciones que comprenden el mismo
CN107312759B (zh) 2012-09-19 2025-10-28 珍白斯凯尔有限公司 细胞穿透肽、包含该肽的缀合物、及包含该缀合物的组合物
CN110064056B (zh) 2012-09-19 2022-10-28 珍白斯凯尔有限公司 细胞穿透性肽、包含该肽的缀合物、及包含该缀合物的组合物
ES2716870T3 (es) 2013-04-19 2019-06-17 Gemvax & Kael Co Ltd Composición para el tratamiento y prevención de lesión isquémica
CN105535931A (zh) 2013-06-07 2016-05-04 凯尔杰姆维克斯有限公司 在癌症免疫疗法中有用的生物标记
EP3011967B1 (en) 2013-06-21 2020-06-17 Gemvax & Kael Co., Ltd. Hormone secretion regulator, composition containing same, and method for controlling hormone secretion using same
CN103555729B (zh) * 2013-10-14 2016-08-24 成都华创生物技术有限公司 一种改造的trail基因序列、表达方法及应用
JP6382972B2 (ja) 2013-10-23 2018-08-29 ジェムバックス アンド カエル カンパニー，リミティド 前立腺肥大治療用及びその予防用の組成物
JP6553605B2 (ja) 2013-11-22 2019-07-31 ジェムバックス アンド カエル カンパニー，リミティド 血管新生抑制活性を有するペプチド、及びそれを含む組成物
JP6367950B2 (ja) 2013-12-17 2018-08-01 ジェムバックス アンド カエル カンパニー，リミティド 前立腺癌治療用組成物
CN106456697B (zh) 2014-04-11 2019-12-17 珍白斯凯尔有限公司 具有纤维化抑制活性的肽和含有其的组合物
KR102232320B1 (ko) 2014-04-30 2021-03-26 주식회사 젬백스앤카엘 장기, 조직 또는 세포 이식용 조성물, 키트 및 이식 방법
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
WO2016123578A1 (en) 2015-01-30 2016-08-04 The Regents Of The University Of California Protein delivery in primary hematopoietic cells
CN107405380B (zh) 2015-02-27 2021-04-20 珍白斯凯尔有限公司 用于预防听觉损伤的肽及其包含该肽的组合物
EP3973977A1 (en) 2015-03-31 2022-03-30 Ildong Pharm Co., Ltd. Pharmaceutical composition for preventing and treating eye diseases, containing, as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused
WO2016190660A1 (ko) 2015-05-26 2016-12-01 주식회사 젬백스앤카엘 신규 펩티드 및 이를 포함한 조성물
KR101647804B1 (ko) * 2015-06-24 2016-08-11 한국과학기술연구원 신규 세포투과 펩타이드 및 이의 용도
EP3318265B1 (en) 2015-07-02 2021-08-18 Gemvax & Kael Co., Ltd. Peptide having anti-viral effect and composition containing same
AU2016335287A1 (en) 2015-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide drugs
WO2017127567A1 (en) * 2016-01-19 2017-07-27 Genebiologics, Llc Production of arginine-rich proteins and use as a fertilizer and germination enhancer
ES2949697T3 (es) 2016-04-07 2023-10-02 Gemvax & Kael Co Ltd Péptido que tiene efectos de aumento de la actividad telomerasa y de extensión de los telómeros, y composición que contienen el mismo
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
WO2018065634A1 (en) 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
MA50213A (fr) * 2016-12-16 2020-07-22 Avixgen Inc Peptide de transduction cytoplasmique et messager intracellulaire le comprenant
JP2019099578A (ja) * 2017-12-06 2019-06-24 参天製薬株式会社 細胞膜透過性ペプチドを含有する眼科用医薬組成物
KR101933217B1 (ko) 2017-12-28 2018-12-27 (주) 에빅스젠 피부 염증 억제용 펩티드 및 이를 포함하는 피부 염증 예방 또는 치료용 조성물
AR117565A1 (es) 2018-04-03 2021-08-18 Ngm Biopharmaceuticals Inc Agentes de unión a c3 y método de uso de los mismos
JP7442823B2 (ja) 2018-04-06 2024-03-05 シプルメット・ゲーエムベーハー 治療用ペプチド及び治療用タンパク質の経粘膜送達のための薬学的組成物
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
US20210386788A1 (en) 2018-10-24 2021-12-16 Obsidian Therapeutics, Inc. Er tunable protein regulation
CN109575107B (zh) * 2018-11-26 2022-03-08 上海华新生物高技术有限公司 一种细胞穿透肽及可表达口服干扰素的双歧杆菌
CN109553659B (zh) * 2018-11-26 2022-06-21 上海华新生物高技术有限公司 一种细胞穿透肽及透皮干扰素
WO2020256150A1 (ja) 2019-06-21 2020-12-24 滋 天野 細胞透過性ペプチド
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
CN116419750A (zh) 2020-09-07 2023-07-11 西普鲁梅有限公司 改进的glp-1受体激动剂的药物制剂
KR20230090333A (ko) 2020-10-16 2023-06-21 각코호우징 조쇼 가쿠엔 조성물
CN114805593A (zh) * 2021-01-19 2022-07-29 盛世泰研(广东)健康科技有限公司 一种具有穿膜功能的Penetratin-hSOD1及其制备方法与应用
KR20220157778A (ko) * 2021-05-21 2022-11-29 원큐어젠 주식회사 세포 투과성 펩타이드 및 글루카곤 유사 펩타이드-1 수용체 작용제를 포함하는 복합체
JP2025508982A (ja) 2022-03-03 2025-04-10 サイプルメド ゲーエムベーハー 治療用ペプチドおよびタンパク質の改善された経口医薬製剤
CN114984193A (zh) * 2022-06-07 2022-09-02 盛世泰研(广东)健康科技有限公司 一种psf-sod1与透明质酸的组合物及其制备方法与应用
CN115944713A (zh) * 2022-12-27 2023-04-11 中国人民解放军军事科学院军事医学研究院 一种神经营养因子和穿透肽组合物及其应用
WO2025009503A1 (ja) * 2023-07-03 2025-01-09 メスキュージェナシス株式会社 細胞膜透過性を有するペプチドおよびそのスクリーニング方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE173016T1 (de) 1992-08-21 1998-11-15 Biogen Inc Von tat abgeleitete transportpolypeptide
JP3770666B2 (ja) 1996-09-20 2006-04-26 株式会社ティ・ティ・エス技術研究所 経粘膜吸収製剤用組成物
CA2350919A1 (en) * 1998-11-13 2000-05-25 Cyclacel Limited Antennapedia homeodomain helix 3 derived translocation vectors
JPWO2004037859A1 (ja) 2002-10-11 2006-02-23 株式会社三和化学研究所 Ｇｌｐ−１誘導体及びその経粘膜吸収型製剤
US7385027B2 (en) * 2003-01-07 2008-06-10 University Of Kentucky Research Foundation Membrane-permeable peptide capable of calpain inhibition
JP2005185271A (ja) * 2003-12-03 2005-07-14 Credia Japan:Kk 膜透過性ペプチド核酸
AU2005304973A1 (en) * 2004-11-05 2006-05-18 Palingen, Inc. Antibody induced cell membrane wounding
MX2010009148A (es) * 2008-02-28 2010-12-06 Toray Industries Composicion farmaceutica para la administracion transnasal.
CN102580061B (zh) * 2011-12-01 2015-04-22 武汉健宇生物医药科技有限公司 一种鼻用型胰岛素制剂及制备方法

Also Published As

Publication number Publication date
EP2433953A1 (en) 2012-03-28
CA2762551A1 (en) 2010-11-25
KR101783291B1 (ko) 2017-09-29
RU2011151877A (ru) 2013-06-27
AU2010250452A1 (en) 2011-11-10
JP5653214B2 (ja) 2015-01-14
CA2762551C (en) 2016-11-22
RU2548807C2 (ru) 2015-04-20
BRPI1008230A2 (pt) 2016-03-08
KR20120064650A (ko) 2012-06-19
JPWO2010134537A1 (ja) 2012-11-12
BRPI1008230B1 (pt) 2019-05-28
EP2433953B1 (en) 2015-07-08
WO2010134537A1 (ja) 2010-11-25
AU2010250452B2 (en) 2014-06-05
ES2546304T3 (es) 2015-09-22
CN102428096B (zh) 2015-03-25
US8772449B2 (en) 2014-07-08
EP2433953A4 (en) 2013-06-05
PL2433953T3 (pl) 2015-12-31
CN102428096A (zh) 2012-04-25
US20120065124A1 (en) 2012-03-15

Similar Documents

Publication Publication Date Title
MX2011011960A (es) Peptidos penetradores de celulas.
NZ598356A (en) Antigenic tau peptides and uses thereof
ES2616658T3 (es) Péptidos que mimetizan el factor de crecimiento y sus usos
EP2594581A3 (en) Peptide vaccines with Seq Id No: 178, 174, 186 or 194 for cancers expressing tumor-associated antigens
IN2014CN02050A (es)
UA111141C2 (uk) Рекомбінантні антигени рсв
NZ600731A (en) Oxyntomodulin peptide analogue
MX2010002001A (es) Peptido cdca1 y agente farmaceutico que comprende elmismo.
NZ600690A (en) Fkbp-l and uses thereof
NZ600732A (en) Oxyntomodulin peptide analogue
NZ602845A (en) Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof
WO2009025116A1 (ja) Cdh3ペプチド及びこれを含む薬剤
CO6362047A2 (es) Virus sincitial respiratorio vivo atenuado
MX2008009493A (es) Peptido novedoso y uso del mismo.
WO2008113536A8 (en) Neurotrophic peptides
MX2009007261A (es) Vacuna de peptido foxp3.
NZ586074A (en) LCLRP peptides, constructs and uses thereof
NZ598932A (en) Identification of antigenic peptides from multiple myeloma cells
WO2010057242A3 (de) Vakzin
MX2010005816A (es) Epítopos de péptido de stat3.
AR083766A1 (es) Peptido inmunogenico
NZ592461A (en) Rab6kifl/kif20a epitope peptide and vaccines containing the same
WO2009105780A3 (en) Mntf peptide compositions and methods of use
WO2011061720A3 (en) Viral citrullinated peptides and uses thereof
NZ603379A (en) Ect2 peptides and vaccines including the same

Legal Events

Date Code Title Description
FG Grant or registration